{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T23:10:09Z","timestamp":1764889809071,"version":"3.46.0"},"reference-count":46,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"unspecified","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","award":["D43TW010937"],"award-info":[{"award-number":["D43TW010937"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015777","name":"Division of Research Capacity Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015777","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002806","name":"Discovery Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002806","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,9,15]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The glucose-lowering drug metformin has shown promise in non-diabetic conditions for improving endothelial dysfunction, but the literature of metformin\u2019s effect on endothelial dysfunction and the biomarkers used to measure endothelial dysfunction have not yet been synthesised.<\/jats:p>\n                    <jats:p>We aimed to map the extent and nature of the existing research related to metformin for endothelial dysfunction in non-diabetic non-communicable diseases (NCDs). This scoping review was conducted following the methodological framework by Arksey and O\u2019Malley and the recommendations from the Joanna Briggs Institute, and was reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Eligibility criteria<\/jats:title>\n                    <jats:p>We considered any peer-reviewed studies in adult humans on the use of metformin for endothelial dysfunction in non-diabetic NCDs. Narrative reviews, expert opinion, preclinical studies and qualitative studies were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Sources of evidence<\/jats:title>\n                    <jats:p>An unrestricted search was conducted on four electronic databases and three registries from inception to October 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Charting methods<\/jats:title>\n                    <jats:p>Data charting was performed using predetermined data extraction headings. We used a systematic charting method and narrative synthesis to organise, synthesise and report the data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 56 studies comprising 4620 participants (71.7% female). Polycystic ovarian syndrome was the most investigated NCD (57.1% of studies). 19 distinct biomarkers of endothelial dysfunction were identified, with flow-mediated dilation being the most frequently assessed (18 studies, 745 participants). Metformin showed a trend towards improvement for 7\/19 (36.8%) biomarkers. Male participants were underrepresented in the literature and only five studies (9%) were conducted in the global south, potentially limiting the generalisability of repurposed metformin in diverse populations or settings. Studies with an active comparator reported a significant difference between the metformin and comparator groups in 20% (4\/20), in contrast to studies without an active comparator (placebo or pre\u2013post studies) reporting significant results favouring metformin in 83.3% (30\/36). A knowledge gap also exists for metformin use in people with HIV, given that they are known to develop cardiovascular NCDs at a twofold higher rate than their HIV-negative counterparts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While there is a growing evidence base supporting metformin as treatment for endothelial dysfunction in non-diabetic NCDs, our scoping review highlighted knowledge gaps in optimal biomarker selection and dosing strategies, and applications in a broader range of NCDs, including in people with HIV. More primary and secondary research using robust methodologies and study designs is needed to determine the quantitative effect of metformin on endothelial dysfunction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-100017","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T07:40:25Z","timestamp":1759822825000},"page":"e100017","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Metformin for endothelial dysfunction in non-diabetic disorders: a scoping review"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6464-4257","authenticated-orcid":false,"given":"Roland","family":"van Rensburg","sequence":"first","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, Stellenbosch University Faculty of Medicine and Health Sciences, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anel","family":"Schoonees","sequence":"additional","affiliation":[{"name":"Centre for Evidence-Based Health Care, Department of Global Health, Stellenbosch University Faculty of Medicine and Health Sciences, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed W","family":"Ali","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, Stellenbosch University Faculty of Medicine and Health Sciences, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3021-5101","authenticated-orcid":false,"given":"Gert U","family":"Van Zyl","sequence":"additional","affiliation":[{"name":"Division of Medical Virology, Department of Pathology, Stellenbosch University Faculty of Medicine and Health Sciences, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1815-5150","authenticated-orcid":false,"given":"Eric H","family":"Decloedt","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, Stellenbosch University Faculty of Medicine and Health Sciences, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"unstructured":"Noncommunicable diseases. Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/noncommunicable-diseases [Accessed 26 Jun 2024].","key":"2025120415055167000_15.10.e100017.1"},{"unstructured":"Global Burden of Disease Collaborative Network . Global burden of disease study 2019 (GBD 2019) results. Institute for Health Metrics and Evaluation (IHME); 2020. Available: https:\/\/vizhub.healthdata.org\/gbd-results\/ [accessed 25 Jan 2023]","key":"2025120415055167000_15.10.e100017.2"},{"doi-asserted-by":"publisher","key":"2025120415055167000_15.10.e100017.3","DOI":"10.1056\/NEJMra1109345"},{"doi-asserted-by":"publisher","key":"2025120415055167000_15.10.e100017.4","DOI":"10.1124\/pharmrev.120.000096"},{"key":"2025120415055167000_15.10.e100017.5","doi-asserted-by":"crossref","first-page":"100084","DOI":"10.1016\/j.hsr.2023.100084","article-title":"Endothelial dysfunction and its relation in different disorders: Recent update","volume":"7","author":"Ray","year":"2023","journal-title":"Health Sciences Review"},{"key":"2025120415055167000_15.10.e100017.6","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.pharmthera.2018.07.007","article-title":"Endothelial function and dysfunction: Impact of metformin","volume":"192","author":"Nafisa","year":"2018","journal-title":"Pharmacol Ther"},{"key":"2025120415055167000_15.10.e100017.7","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2018.00185","article-title":"HIV Proteins and Endothelial Dysfunction: Implications in Cardiovascular Disease","volume":"5","author":"Anand","year":"2018","journal-title":"Front Cardiovasc Med"},{"doi-asserted-by":"publisher","key":"2025120415055167000_15.10.e100017.8","DOI":"10.1038\/s41401-022-00998-0"},{"key":"2025120415055167000_15.10.e100017.9","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/clc.23299","article-title":"Inflammatory and cardiovascular diseases biomarkers in chronic hepatitis C virus infection: A review","volume":"43","author":"Babiker","year":"2020","journal-title":"Clin Cardiol"},{"doi-asserted-by":"publisher","key":"2025120415055167000_15.10.e100017.10","DOI":"10.1161\/cir.0000000000000695"},{"key":"2025120415055167000_15.10.e100017.11","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1016\/S2352-3018(20)30036-9","article-title":"HIV and cardiovascular disease","volume":"7","author":"So-Armah","year":"2020","journal-title":"Lancet HIV"},{"doi-asserted-by":"publisher","key":"2025120415055167000_15.10.e100017.12","DOI":"10.1161\/CIRCULATIONAHA.117.033369"},{"doi-asserted-by":"publisher","key":"2025120415055167000_15.10.e100017.13","DOI":"10.1016\/j.numecd.2009.08.006"},{"key":"2025120415055167000_15.10.e100017.14","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22083850","article-title":"Endothelial Dysfunction, Inflammation and Coronary Artery Disease: Potential Biomarkers and Promising Therapeutical Approaches","volume":"22","author":"Medina-Leyte","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025120415055167000_15.10.e100017.15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1248\/jhs.54.1","article-title":"Pharmacological Interventions to Prevent Vascular Endothelial Dysfunction: Future Directions","volume":"54","author":"Balakumar","year":"2008","journal-title":"J Health Sci (El Monte)"},{"doi-asserted-by":"publisher","key":"2025120415055167000_15.10.e100017.16","DOI":"10.1111\/bph.13517"},{"key":"2025120415055167000_15.10.e100017.17","doi-asserted-by":"crossref","first-page":"155223","DOI":"10.1016\/j.metabol.2022.155223","article-title":"Metformin: Is it a drug for all reasons and diseases?","volume":"133","author":"Triggle","year":"2022","journal-title":"Metab Clin Exp"},{"key":"2025120415055167000_15.10.e100017.18","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/dom.13262","article-title":"Epigenetic effects of metformin: From molecular mechanisms to clinical implications","volume":"20","author":"Bridgeman","year":"2018","journal-title":"Diabetes Obes Metab"},{"doi-asserted-by":"publisher","key":"2025120415055167000_15.10.e100017.19","DOI":"10.3389\/fphar.2020.00635"},{"key":"2025120415055167000_15.10.e100017.20","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1515\/jbcpp-2022-0252","article-title":"Metformin: new applications for an old drug","volume":"34","author":"Naseri","year":"2023","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"2025120415055167000_15.10.e100017.21","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa338","article-title":"Repurposing Metformin in Nondiabetic People With HIV: Influence on Weight and Gut Microbiota","volume":"7","author":"Isnard","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2025120415055167000_15.10.e100017.22","doi-asserted-by":"crossref","first-page":"388","DOI":"10.14740\/jocmr2922e","article-title":"Effect of Metformin on Different Non-Diabetes Related Conditions, a Special Focus on Malignant Conditions: Review of Literature","volume":"9","author":"Abdelgadir","year":"2017","journal-title":"J Clin Med Res"},{"doi-asserted-by":"publisher","key":"2025120415055167000_15.10.e100017.23","DOI":"10.1038\/s41574-023-00833-4"},{"doi-asserted-by":"publisher","key":"2025120415055167000_15.10.e100017.24","DOI":"10.2337\/dc08-1171"},{"unstructured":"Metformin in normoglycemic obesity: a systematic review | ICEECE2012 | 15th international & 14th European congress of endocrinology | endocrine abstracts. Available: https:\/\/www.endocrine-abstracts.org\/ea\/0029\/ea0029p1181 [Accessed 29 Jun 2024].","key":"2025120415055167000_15.10.e100017.25"},{"doi-asserted-by":"publisher","key":"2025120415055167000_15.10.e100017.26","DOI":"10.1111\/joim.12128"},{"doi-asserted-by":"publisher","key":"2025120415055167000_15.10.e100017.27","DOI":"10.2337\/dc18-2356"},{"key":"2025120415055167000_15.10.e100017.28","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-019-0931-0","article-title":"Pericoronary fat inflammation and Major Adverse Cardiac Events (MACE) in prediabetic patients with acute myocardial infarction: effects of metformin","volume":"18","author":"Sardu","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"2025120415055167000_15.10.e100017.29","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9080904","article-title":"Metformin Therapy Effects on the Expression of Sodium-Glucose Cotransporter 2, Leptin, and SIRT6 Levels in Pericoronary Fat Excised from Pre-Diabetic Patients with Acute Myocardial Infarction","volume":"9","author":"Sardu","year":"2021","journal-title":"Biomedicines"},{"doi-asserted-by":"publisher","key":"2025120415055167000_15.10.e100017.30","DOI":"10.1016\/j.jclinepi.2020.10.009"},{"doi-asserted-by":"crossref","unstructured":"Aromataris E , Lockwood C , Porritt K , et al , eds. JBI manual for evidence synthesis. JBI, 2024.","key":"2025120415055167000_15.10.e100017.31","DOI":"10.46658\/JBIMES-24-01"},{"doi-asserted-by":"publisher","key":"2025120415055167000_15.10.e100017.32","DOI":"10.7326\/M18-0850"},{"doi-asserted-by":"publisher","key":"2025120415055167000_15.10.e100017.33","DOI":"10.1016\/j.jclinepi.2016.01.021"},{"unstructured":"Higgins J , Thomas J , Chandler J , et al , eds. Cochrane handbook for systematic reviews of interventions. Version 6. Cochrane, 2024.","key":"2025120415055167000_15.10.e100017.34"},{"doi-asserted-by":"publisher","key":"2025120415055167000_15.10.e100017.35","DOI":"10.7326\/0003-4819-143-5-200509060-00009"},{"key":"2025120415055167000_15.10.e100017.36","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/QAD.0b013e32834f33cc","article-title":"Effects of lifestyle modification and metformin on atherosclerotic indices among HIV-infected patients with the metabolic syndrome","volume":"26","author":"Fitch","year":"2012","journal-title":"AIDS"},{"doi-asserted-by":"publisher","key":"2025120415055167000_15.10.e100017.37","DOI":"10.1056\/NEJMoa2304146"},{"key":"2025120415055167000_15.10.e100017.38","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25690","article-title":"Cost-effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States","volume":"24","author":"Boettiger","year":"2021","journal-title":"J Int AIDS Soc"},{"key":"2025120415055167000_15.10.e100017.39","first-page":"183","article-title":"Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome","volume":"1","author":"Hadi","year":"2005","journal-title":"Vasc Health Risk Manag"},{"key":"2025120415055167000_15.10.e100017.40","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2337\/cd21-0043","article-title":"Recommendations for Practical Use of Metformin, a Central Pharmacological Therapy in Type 2 Diabetes","volume":"40","author":"Vieira","year":"2022","journal-title":"Clin Diabetes"},{"doi-asserted-by":"publisher","key":"2025120415055167000_15.10.e100017.41","DOI":"10.2337\/dc11-1465"},{"doi-asserted-by":"publisher","key":"2025120415055167000_15.10.e100017.42","DOI":"10.1016\/S0002-9343(97)00254-4"},{"doi-asserted-by":"publisher","key":"2025120415055167000_15.10.e100017.43","DOI":"10.1093\/humrep\/des262"},{"doi-asserted-by":"publisher","key":"2025120415055167000_15.10.e100017.44","DOI":"10.1016\/j.jacc.2004.08.062"},{"doi-asserted-by":"publisher","key":"2025120415055167000_15.10.e100017.45","DOI":"10.1186\/1471-2288-14-135"},{"unstructured":"Cochrane Training . Chapter 6: choosing effect measures and computing estimates of effect. Available: https:\/\/training.cochrane.org\/handbook\/archive\/v6.3\/chapter-06#section-6-5-2 [Accessed 25 Jul 2024].","key":"2025120415055167000_15.10.e100017.46"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-100017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T23:07:43Z","timestamp":1764889663000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-100017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":46,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,6]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/bmjopen-2025-100017"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-100017","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}